SELECTION OF MODERN SAFE AND EFFECTIVE NSAID IN PATIENTS WITH CONCOMITANT (COMORBID) DISEASES


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

In clinical practice, we are often faced with patients who have back pain and joint pain in combination with a variety of comorbid medical conditions (arterial hypertension, coronary artery disease, cerebrovascular disease, chronic obstructive pulmonary disease, liver disease, kidney disease, etc.). Therefore, the issues of frequency of systemic complications of therapy with nonsteroidal anti-inflammatory drugs (NSAIDs) and its potential interaction with drugs receiving by the patient have identified the relevance of this article. Now it is proved that among a number of NSAIDs, the original meloxicam (Movalis) is characterized not only by low-risk for the development of comorbid somatic side effects, but a good safety spectrum in combination therapy, making it possible to use this drug in general medical practice.

Толық мәтін

Рұқсат жабық

Авторлар туралы

E. Akarachkova

SRD of Neurology SRC SBEI HPE "First MSMU n.a. I.M. Sechenov" of RMH; International Society" Stress under control"

Email: nevroius@mail.ru
MD, Leading Researcher at Laboratory of Pathology of the Autonomic Nervous system, Research Department of Neurology Moscow

O. Gromova

SBEI HPE "Ivanovo State Medical Academy"

Department of Pharmacology with Clinical Pharmacology Ivanovo

O. Kotova

SRD of Neurology SRC SBEI HPE "First MSMU n.a. I.M. Sechenov" of RMH

Moscow

Әдебиет тізімі

  1. Coxib and traditional NSAID Trialists' Collaboration. Bhala N., Emberson J., Merhi A., Abramson S., Arber N., Baron J.A., Bombardier C., Cannon C., Farkouh M.E., FitzGerald G.A., Goss P., Halls H., Hawk E., Hawkey C., Hennekens C., Hochberg M., Holland L.E., Kearney P.M., Laine L., Lanas A., Lance P., Laupacis A., Oates J., Patrono C., Schnitzer T.J., Solomon S., Tugwell P., Wilson K., Wittes J., Baigent C. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894): 769-79.
  2. Schoenfeld P. Gastrointestinal safety profile of meloxicam: a metaanalysis and systematic review of randomized controlled trials. Am. J. Med. 1999;107:48-54.
  3. Maehata Y., Esaki M., Morishita T., Kochi S., Endo S., Shikata K., Kobayashi H., Matsumoto T. Small bowel injury induced by selective cyclo-oxygenase-2 inhibitors: a prospective, double-blind, randomized clinical trial comparing celecoxib and meloxicam. J. Gastroenterol. 2012;47(4):587-95.
  4. Raber A., Heras J., Costa J., et al. Incidence of spontaneous notifications of adverse reactions with aceclofenac, meloxicam, and rofecoxib during the first year after marketing in the United Kingdom. Ther. Clin. Risk Manag. 2007;5(2):225-50.
  5. Mukherjee D., Nissen S.E., Topol E.J. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286(8): 954-59.
  6. Helin-Salmivaara A., Virtanen A., Vesalainen R., Grönroos J.M., Klaukka T., Idänpään-Heikkilä J.E., Huupponen R. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. Eur. Heart J. 2006;27(14):1657-65.
  7. Varas-Lorenzo C.,Riera-Guardia N.,Calingaert B., Castellsague J., Salvo F., Nicotra F., Sturkenboom M., Perez-Gutthann S. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol. Drug. Saf. 2015;22(6):559-70.
  8. Layton D., Hughes K., Harris S., Shakir S.A. Comparison of the incidence rates of thromboembolic events reported for patients prescribed celecoxib and meloxicam in general practice in England using Prescription-Event Monitoring (PEM) data. Rheumatology (Oxford). 2005;42(11):1554-64.
  9. Haag M.D., Bos M.J., Hofman A., Koudstaal P.J., Breteler M.M., Stricker B.H. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs and risk of stroke. Arch. Intern. Med. 2008;168(11):1219-24.
  10. Van Ryn J., Kink-Eiband M., Kuritsch I., Feifel U., Hanft G., Wallenstein G., Trummlitz G., Pairet M. Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. J. Clin. Pharmacol. 2004;44 (7):777-84.
  11. Senna G., Bilo M., Antonicelli L., Schiappoli M., Crivellaro M.A., Bonadonna P., Dama A.R. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients. Eur. Ann. Allergy. Clin. Immunol. 2004;56(6):215-18.
  12. Goksel O., Aydin O., Misirligil Z., Demirel Y.S., Bavbek S. Safety of meloxicam in patients with aspirin/non-steroidal anti-inflammatory drug-induced urticaria and angioedema. J. Dermatol. 2010;57(11):975-79.
  13. Hassan M.H., El-Beshbishy H.A., Aly H., Attia S.M., Bahashwan S.A., Ghobara M.M. Modulatory effects of meloxicam on cardio-toxicity and antitumor activity of doxorubicin in mice. Cancer Chemother. Pharmacol. 2014;74(5):559-69.
  14. Singh G., Lanes S., Triadafilopoulos G. Risk of serious upper gastrointestinal and cardiovascular thromboembolic complications with meloxicam. Am. J. Med. 2004;117(2):100-6.
  15. Bevis P.J, Bird H.A., Lapham G. An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal impairment. Br. J. Rheumatol. 1996;35(1):56-60.
  16. Huerta C, Castellsague J., Varas-Lorenzo C., Garcia Rodriguez L.A. Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population. Am. J. Kidney. Dis. 2005; 45(3):531-39.
  17. Winkelmayer W.C., Walker S.S., Mogun H., Solomon D.H. Nonselective and cyclooxygenase-2-selective NSAIDs and acute kidney injury. Am. J. Med. 2008;121(12):1092-98.
  18. Asghar W., Jamali F. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology. 2015;23(1):1-16.
  19. Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J. Gastroenterol. 2010;16(45): 5651-61.
  20. Traversa G., Bianchi C., Da Cas R., Abraha I., Menniti-Ippolito F., Venegoni M. Cohort study of hepatotoxity associated with nimesulide and other non-steroidal antiinflammatory drugs. BMJ. 2003;327:18-22.
  21. Walker S.L.,Kennedy F.,Niamh N.,McCormick P.A. Nimesulide associated fulminant hepatic failure. Pharmacoepidemiol. Drug. Saf. 2008;17(11):1108-12.
  22. Monteiro J.P., Martins A.F., Lucio M., Reis S., Pinheiro T.J.,Geraldes C.F.,Oliveira P.J.,Jurado A.S. Nimesulide interaction with membrane model systems: are membrane physical effects involved in nimesulide mitochondrial toxicity? Toxicol. In Vitro. 2011;25(6):1215-23.
  23. Singh B.K., Tripathi M., Pandey P.K., Kakkar P. Nimesulide aggravates redox imbalance and calcium dependent mitochondrial permeability transition leading to dysfunction in vitro. Toxicology. 2010;275(1-3):1-9.
  24. Lapeyre-Mestre M., de Castro A.M., Bareille M.P., Del Pozo J.G., Requejo A.A., Arias L.M., Montastruc J.L., Carvajal A. Non-steroidal anti-inflammatory drug-related hepatic damage in France and Spain: analysis from national spontaneous reporting systems. Fundam. Clin. Pharmacol. 2006;20(4):391-95.
  25. Kagawa T., Kojima S., Shiraishi K., Hirose S., Arase Y., Takashimizu S., Watanabe N.,Nagata N., Numata M., Shiozawa H., Nishizaki Y., Toki M., Sugita T., Nomura K., Sakaguchi T., Atsukawa K., Tajima H., Tei Y., Inomoto T., Mine T. Meloxicam as an adjuvant to peginterferon-a-2a and ribavirin treatment for genotype 1 chronic hepatitis C: A randomized trial. Hepatol. Res. 2013;43(9):925-32.
  26. Solomon D.H., Glynn R.J., Rothman K.J., Schneeweiss S., Setoguchi S., Mogun H., Avorn J., Stürmer T. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum. 2008;59(8):1097-104.
  27. Каратеев А.Е. Мелоксикам: «золотая середина» нестероидных противовоспалительных препаратов. Терапевт. арх. 2014;5:99-105.
  28. Акарачкова Е.С., Котова О.В. НВПП в терапии боли в спине: фокус на эффективность и безопасность. Manage Pain. 2015;3.
  29. Barozzi N., Peeters G.G., Tett S.E. Actions following adverse drug events - how do these influence uptake and utilisation of newer and/ or similar medications? BMC Health Serv. Res. 2015;15:498.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2016

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>